Skip to main content

Table 2 Identifying a history of major IHD or cerebrovascular disease using GP diagnoses as a reference standard

From: Identification of major cardiovascular events in patients with diabetes using primary care data

Drug (at least 1 prescription) TP FP TN FN Sens (95 % CI) Spec (95 % CI) PPV (95 % CI) NPV (95 % CI)
IHD/cerebrovascular history
 Vitamin K antagonists 424 1029 12996 2010 17 (16–19) 93 (92–93) 29 (27–32) 87 (86–87)
 Platelet aggregation inhibitors 1696 2500 11525 738 70 (68–72) 82 (82–83) 40 (39–42) 94 (94–94)
 Nitrates 487 441 13584 1947 20 (18–22) 97 (97–97) 52 (49–56) 87 (87–88)
 Vitamin K antagonists/Platelet aggregation inhibitors 2045 3441 10584 389 84 (83–85) 75 (75–76) 37 (36–39) 96 (96–97)
 Vitamin K antagonists/Platelet aggregation inhibitors/Nitrates 2077 3519 10506 357 85 (84–87) 75 (75–76) 37 (36–38) 97 (96–97)
IHD history
 Vitamin K antagonists 354 1099 13453 1553 19 (17–20) 92 (92–93) 24 (22–27) 90 (89–90)
 Platelet aggregation inhibitors 1312 2884 11668 595 69 (67–71) 80 (80–81) 31 (30–33) 95 (95–96)
 Nitrates 466 462 14090 1441 24 (23–26) 97 (97–97) 50 (47–53) 91 (90–91)
 Vitamin K antagonists/Platelet aggregation inhibitors 1603 3883 10669 304 84 (82–86) 73 (73–74) 29 (28–30) 97 (97–98)
 Vitamin K antagonists/Platelet aggregation inhibitors/Nitrates 1907 3961 10591 0 100 (100–100) 73 (72–74) 32 (31–34) 100 (100–100)
Cerebrovascular history
 Vitamin K antagonists 119 1334 14424 582 17 (14–20) 92 (91–92) 8 (7–10) 96 (96–96)
 Platelet aggregation inhibitors 506 3690 12068 195 72 (69–75) 77 (76–77) 12 (11–13) 98 (98–99)
 Nitrates 67 861 14897 634 10 (7–12) 95 (94–95) 7 (6–9) 96 (96–96)
 Vitamin K antagonists/Platelet aggregation inhibitors 604 4882 10876 97 86 (83–89) 69 (68–70) 11 (10–12) 99 (99–99)
 Vitamin K antagonists/Platelet aggregation inhibitors/Nitrates 604 4992 10766 97 86 (83–89) 68 (68–69) 11 (10–12) 99 (99–99)
  1. Abbreviations: IHD ischaemic heart disease, GP general practitioner, TP true positive, FP false positive, TN true negative, FN false negative, Sens sensitivity, Spec specificity, PPV positive predictive value, NPV negative predictive value